Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Exelixis (EXEL) PT Raised to $29 at Stephens
October 30, 2024 6:27 AM EDTStephens analyst Sudan Loganathan raised the price target on Exelixis (NASDAQ: EXEL) to $29.00 (from $23.00) while maintaining a Equal Weight rating.
The analyst comments "EXEL reported 3Q24 financial results yesterday (10/29/2024) after market close and provided regulatory and business updates. Key highlights on the... More
Exelixis (EXEL) PT Raised to $38 at Citi
October 30, 2024 5:47 AM EDTCiti analyst David Lebowitz raised the price target on Exelixis (NASDAQ: EXEL) to $38.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Exelixis reported 3Q24 financial results, beating consensus on top-line revenue and GAAP EPS due to continued strength of cabozantinib. Total... More



